Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) Operating Margin (2021 - 2025)

Oncology Institute (TOI) has disclosed Operating Margin for 5 consecutive years, with 5.9% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Margin rose 797.0% year-over-year to 5.9%, compared with a TTM value of 8.92% through Sep 2025, up 784.0%, and an annual FY2024 reading of 15.28%, up 847.0% over the prior year.
  • Operating Margin was 5.9% for Q3 2025 at Oncology Institute, up from 9.36% in the prior quarter.
  • Across five years, Operating Margin topped out at 2.24% in Q2 2021 and bottomed at 78.07% in Q4 2021.
  • Average Operating Margin over 5 years is 21.01%, with a median of 16.97% recorded in 2023.
  • Peak annual rise in Operating Margin hit 4295bps in 2022, while the deepest fall reached -2988bps in 2022.
  • Year by year, Operating Margin stood at 78.07% in 2021, then skyrocketed by 55bps to 35.11% in 2022, then soared by 49bps to 17.82% in 2023, then surged by 33bps to 11.9% in 2024, then surged by 50bps to 5.9% in 2025.
  • Business Quant data shows Operating Margin for TOI at 5.9% in Q3 2025, 9.36% in Q2 2025, and 9.49% in Q1 2025.